Back to top
more

Geron (GERN)

(Delayed Data from NSDQ)

$1.28 USD

1.28
11,318,845

-0.02 (-1.54%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $1.29 +0.01 (0.78%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Geron (GERN) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Zacks Equity Research

Company News for May 12, 2023

by Zacks Equity Research

Companies in The News Are: CYBR,GERN,TPR,DDS

Zacks Equity Research

Geron (GERN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Geron (GERN) delivered earnings and revenue surprises of 22.22% and 85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 55.56% and 8.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seer, Inc. (SEER) delivered earnings and revenue surprises of -2.70% and 1.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.29% and 163.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Is Bluebird (BLUE) Up 17.2% Since Last Earnings Report?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report?

by Zacks Equity Research

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Geron (GERN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Geron (GERN) closed the most recent trading day at $2.30, moving -1.71% from the previous trading session.

Zacks Equity Research

Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Geron (GERN) delivered earnings and revenue surprises of 9.09% and 11.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Protagonist (PTGX) Up on Positive Results From FRONTIER Study

by Zacks Equity Research

Protagonist (PTGX) gains as the phase II study, conducted by Janssen, achieves its primary goal.

Zacks Equity Research

Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales Increase

by Zacks Equity Research

Intercept (ICPT) posts a narrower loss in Q4 due to higher revenues.

Zacks Equity Research

Amicus (FOLD) Q4 Earnings Miss, Galafold Sales Beat Estimates

by Zacks Equity Research

Amicus (FOLD) posts a wider-than-expected fourth-quarter loss but strong sales of its solely marketed drug Galafold drive the top line.

Zacks Equity Research

Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 1.72% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

FATE reports a narrower loss and higher collaboration revenues for the fourth quarter.

Zacks Equity Research

Geron (GERN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Geron (GERN) closed the most recent trading day at $2.74, moving +1.48% from the previous trading session.

Zacks Equity Research

Geron (GERN) Stock Moves -1.78%: What You Should Know

by Zacks Equity Research

In the latest trading session, Geron (GERN) closed at $2.76, marking a -1.78% move from the previous day.

Zacks Equity Research

Geron (GERN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on updates on Geron's (GERN) lead pipeline candidate when it reports its fourth-quarter earnings.

Zacks Equity Research

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adaptive Biotechnologies (ADPT) and Geron (GERN) have performed compared to their sector so far this year.

Zacks Equity Research

Geron (GERN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Geron (GERN) closed at $2.69 in the latest trading session, marking a +1.13% move from the prior day.

Zacks Equity Research

Geron (GERN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Geron (GERN) closed at $3.01 in the latest trading session, marking a -1.31% move from the prior day.

Zacks Equity Research

Geron (GERN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Geron (GERN) closed the most recent trading day at $3.34, moving -1.18% from the previous trading session.

Zacks Equity Research

Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Geron (GERN) have performed compared to their sector so far this year.

Zacks Equity Research

Geron (GERN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Geron (GERN) closed at $3.34, marking a -0.89% move from the previous day.

Zacks Equity Research

Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?

by Zacks Equity Research

Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and Geron (GERN) have performed compared to their sector so far this year.